Vitrolife's Press Release of Annual Accounts 2003

Increase in sales with profit and positive cash flow

· Total net sales were SEK 96,3 million (103,3 - net sales of SEK 28,1 million is from assigned companies)

· Core business net sales increased by 28 per cent, in spite of negative currency influence, and amounted to SEK 96,3 million (75,2)

· Gross profit totalled SEK 61,6 million (49,4) and in per cent of turnover of 64 per cent (48)

· The group's net result totalled SEK 44,7 million whereof SEK 42,3 million is an item affecting comparability regarding mainly the sales of Alife (-116,5 whereof items affecting comparability -89,4)

· Operating result for quarter four amounted to SEK 3,0 million (-110,2 whereof -87,6 is items affecting comparability)

· Result per share SEK 2,4 (-6,3)

· Vitrolife divested in August its subsidiary which developed products for aestctic facial surgery based on cross-linked Hyaluronic acid to Mentor Corp., USA for SEK 60 million free of debt plus royalty on future sales

· Vitrolife received market clearance from FDA to marketing EmbryoGlue®

For further information, please contact:

CEO:
Magnus Nilsson
Tel: +46 31 721 80 00
Mobile +46 708 22 80 61
[email protected]

CFO and IR agent:
Anders Sävfält
Tel: +46 31 721 80 00
Mobile: +46 708 22 80 13
[email protected]

Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations focused on three geographic areas.

· Europe/Middle East
· The Americas
· Rest of the World

Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs.